Regulatory Compliance That Scales: Practical Steps for Modern Organizations

Regulatory environments keep shifting, and compliance can’t be a one-off project.

Organizations that treat compliance as an ongoing, scalable function reduce risk, improve operational efficiency, and build trust with customers and regulators. The following framework highlights practical, evergreen steps to build or strengthen a compliance program that adapts to change.

Core components of a scalable compliance program
– Risk assessment: Identify legal, operational, financial, and reputational risks tied to products, services, markets, and third parties. Prioritize by likelihood and impact.
– Policy and procedure lifecycle: Create clear, role-based policies; map procedures to controls; establish review and approval workflows.
– Monitoring and testing: Use continuous controls monitoring and periodic testing to detect gaps early.
– Training and culture: Deliver targeted, role-specific training and reinforce expectations through leadership and performance management.
– Vendor and third-party risk management: Assess vendors before onboarding and monitor ongoing compliance post-contract.
– Incident response and remediation: Define escalation paths, investigation steps, and remediation timelines for compliance breaches.
– Documentation and audit readiness: Keep centralized records of decisions, assessments, and evidence to meet regulatory inquiries.

Practical steps to implement
1.

Start with risk-based prioritization
Not every regulation affects every part of an organization the same way. Map business processes to regulatory obligations and focus resources where the risk is highest. This produces quick wins and builds momentum for broader work.

2. Centralize policy management
Replace scattered documents with a single, searchable policy library.

Include version history, owners, and review dates. Tie each policy to specific legal or regulatory requirements so auditors can trace compliance evidence.

3. Automate routine controls
Manual checklists are error-prone and hard to scale. Automate recurring tasks such as access reviews, transaction monitoring, and vendor attestations.

Automation frees compliance teams for higher-value activities like investigations and program design.

4. Integrate compliance into procurement and engineering
Embed compliance checks into procurement workflows and development pipelines. Require security and privacy sign-offs before contracts are finalized and ensure engineering teams use secure-by-design patterns to reduce downstream compliance costs.

5. Build measurable KPIs
Track metrics such as time-to-remediate, percentage of policies reviewed on schedule, number of high-risk vendors with mitigation plans, and training completion rates.

Use dashboards to surface trends and inform leadership decisions.

6. Maintain regulatory change management
Allocate responsibility for horizon-scanning regulatory updates.

Document potential impacts, conduct gap analyses, and maintain an implementation roadmap for new obligations.

7. Prepare for audits and examinations
Maintain an evidence catalog mapped to common auditor requests. Run mock audits to identify evidence gaps, and cultivate relationships with inspection teams by proactively sharing remediation plans when issues arise.

Common pitfalls to avoid
– Siloed ownership that leaves compliance as an afterthought
– Overreliance on manual processes that don’t scale
– Training that’s generic and not role-specific
– Vendor assessments that stop at initial onboarding

Benefits of a scalable approach
A risk-based, automated, and integrated compliance program reduces regulatory fines and business interruptions, improves customer trust, and lowers the cost of future compliance work. It also positions an organization to respond quickly when regulators change expectations or when new risks emerge.

Next steps
Begin with a focused risk assessment or a targeted automation pilot.

Document findings, secure executive sponsorship, and iterate—small, measurable improvements compound into a resilient compliance capability that supports growth and protects reputation.

In July 2024, Flo Health achieved what no purely digital women’s health company in Europe had accomplished before: a valuation exceeding $1 billion. The milestone came with a $200 million Series C led by General Atlantic—one of the world’s leading growth equity firms.

The femtech company’s rise reflects broader momentum in women’s health investment. Investors have poured nearly $5 billion into the sector over three years—a 60% increase from the prior period. But achieving unicorn status required more than favorable market conditions. It required a product that 420 million people wanted to use.

General Atlantic’s investment thesis centered on category leadership and innovation potential. The company’s recent expansion into perimenopause tracking demonstrates continued product development addressing underserved life stages. The launch of new health features keeps users engaged across decades of their health journey.

Strategic infrastructure investments position the company for the next growth phase. Having achieved FDA readiness without slowing innovation, the platform can pursue clinical-grade features that competitors without regulatory infrastructure cannot.

With development hubs in London, Amsterdam, and Vilnius, the European roots remain strong. But the ambition is global—serving women throughout their entire health journey, everywhere in the world.

For most entrepreneurs, taking a company public is a milestone. For Leen Kawas, it was something closer to a crucible. The biotech scientist and investor had already spent years navigating the complexities of drug development—cell pathways, clinical trials, regulatory frameworks—when she led Athira Pharma through its IPO in 2020. But stepping into the public markets brought a different kind of complexity. One not rooted in science, but in scrutiny.

By the time Athira debuted on the Nasdaq, Kawas had already distinguished herself as a rare figure in biotech: a scientist-CEO who could speak fluently across disciplines—bench research, capital markets, boardroom strategy. Under her leadership, the company advanced therapies targeting neurodegenerative diseases, built a pipeline, and raised over $400 million across private and public rounds. But the act of going public forced a shift. Not in vision, but in visibility.

Unlike many sectors, biotech IPOs often happen before the product hits the market. Investors are not buying into revenue streams. They are buying into probability. That changes the tempo. It compresses time. Every milestone—trial enrollment, safety readouts, manufacturing scale-up—becomes part of a larger narrative that unfolds in real time, under public observation.

Kawas did not shy away from that tension. She approached it the way she approached science: by breaking it into systems. She built an investor relations strategy that educated rather than marketed. She insisted on clarity of risk. And she prepared her team for the psychological weight of public reporting—not just the technical mechanics of filings, but the cultural shift required to sustain focus under market pressure.

The rewards were real. Going public provided Athira with access to capital at a scale private markets couldn’t match. It expanded visibility, attracted talent, and validated the company’s platform in a crowded neurodegeneration space. But Kawas is quick to note that the IPO was not the finish line. It was an acceleration point. One that made the company more accountable, more exposed, and, in some ways, more vulnerable.

That vulnerability is specific to biotech. In most industries, revenue provides insulation. In biotech, outcomes are binary. A trial succeeds or it doesn’t. A molecule works or it doesn’t. For public companies, that reality gets priced in daily. Kawas learned to navigate that volatility not by chasing sentiment, but by returning to the fundamentals: trial design, data integrity, pipeline prioritization.

The challenge, she says, is not just technical. It’s emotional. The public market rewards boldness—but punishes surprises. Leaders must remain transparent without overpromising, optimistic without drifting into hype. For a scientist trained in empirical thinking, that balance is familiar. For a founder navigating market cycles, it becomes a daily discipline.

After stepping down from Athira, Kawas redirected her energy toward broader impact. As managing general partner of Propel Bio Partners, she now backs other founders navigating the early stages of life science innovation. Her work spans diagnostics, therapeutics, and platform tools, but her lens remains the same: support science with operational excellence. Prepare for complexity early. And don’t mistake funding for readiness. Her interview with Billion Success explores this further. 

Her approach is shaped by firsthand experience. She knows what it takes to raise nine-figure rounds. She also knows the strain that comes with turning scientific vision into public accountability. The rewards are substantial—broader access, faster development, amplified visibility—but they are not automatic. They require governance systems that are resilient under pressure. Teams that can absorb uncertainty. Boards that understand both capital and biology.

In this ecosystem, Kawas sees herself as a bridge. Someone who can translate between sectors, coach through inflection points, and help founders design companies that can withstand the demands of growth. She does not glamorize the IPO. She contextualizes it—as a tool, not a goal.

For emerging biotech leaders, that framing matters. The path to the public markets is not linear. It’s a maze of science, timing, and storytelling. Kawas has walked it. She’s made the tough calls—on what to prioritize, how to allocate resources, when to accelerate, and when to pause. That perspective now informs how she evaluates companies, how she supports them, and how she prepares them for the moment when their work moves from the lab to the market—and into the spotlight.

Leen Kawas knows that the IPO is not just a transaction. It’s a transformation. One that demands not only a good product, but a leader who can hold vision and volatility in the same hand. She has done it once. Now, she’s helping others do it better.

Learn more about what Kawas is currently up to at the link below:

Leen Kawas, Ph.D., PharmSci.

When Astromech posted job openings for positions like “Synthetic Data Generation Lead,” “Data Smoothing Expert,” and “Probabilist Programming Researcher,” they inadvertently provided the most transparent window into their technical strategy. In the startup world, job titles often reveal more about company direction than official press releases—especially for stealth-mode AI companies like Astromech, which has raised $30 million while maintaining minimal public presence.

“Probabilist Programming Researcher” is particularly revealing. This emerging field combines programming languages with statistical inference, allowing developers to build models that can reason about uncertainty. It’s especially valuable in domains like drug discovery, genomics, and scientific research, where quantifying confidence is as important as making predictions. Given the founders’ background in biotechnology, this suggests Astromech is building AI tools for scientific applications.

“Synthetic Data Generation Lead” points to another critical challenge in AI development: the shortage of high-quality training data. In regulated industries like healthcare and pharmaceuticals, real data is often unavailable due to privacy concerns or competitive sensitivities. Synthetic data generation allows companies to create artificial datasets that maintain statistical properties of real data while avoiding privacy and intellectual property issues.

“Data Smoothing Expert” indicates sophisticated preprocessing capabilities. Raw biological or scientific data often contains noise, missing values, and inconsistencies that can derail machine learning models. Data smoothing techniques help create cleaner datasets while preserving important signal characteristics.

The “Distributor Intelligence Architect” role suggests Astromech is thinking about deployment and scaling from the beginning. This position likely involves building systems that can distribute AI processing across multiple computing environments—essential for handling the massive datasets standard in genomics and biotechnology research.

These specialized roles indicate Astromech isn’t building general-purpose AI tools. Instead, they appear focused on creating sophisticated platforms for scientific research and biotechnology applications. The company’s connection to Ben Lamm and George Church’s work at Colossal Biosciences reinforces this interpretation.

For job seekers and competitors, parsing startup job postings has become an essential intelligence-gathering technique. In an era where companies guard their technical strategies carefully, hiring announcements often provide the most accurate picture of what they’re actually building.

The lesson for other stealth-mode startups: your job postings are revealing more than you might think.

Biotechnology is one of the most dynamic fields in the global economy, with breakthroughs promising to reshape healthcare and improve millions of lives. But behind the science lies an often-overlooked truth: innovation requires capital. Not just any capital, but patient, strategic investment that recognizes the unique challenges of developing therapies. For Leen Kawas, co-founder and managing general partner of Propel Bio Partners, this understanding is central to her work.

Leen Kawas brings a rare combination of perspectives to the world of biotech investment. She is not only a venture capitalist but also a scientist, inventor, and entrepreneur. Having co-founded Athira Pharma and led it through late-stage clinical trials and a $400 million public offering, she has lived the journey of translating discovery into product. Her conviction today is clear: life science does not thrive on short-term bets but on smart, steady capital that can see the process through.

The Long Arc of Innovation

Kawas emphasizes that developing a therapy is unlike building a typical startup. The path from early research to regulatory approval spans years, often decades. Clinical trials are expensive, regulatory requirements are exacting, and setbacks are common.

She explains that investors accustomed to rapid exits in software or consumer technology often struggle with the patience life science demands. In biotech, failure to recognize this long arc can undermine promising science. Patient capital, by contrast, enables researchers and entrepreneurs to navigate inevitable hurdles without sacrificing the integrity of their work.

Smart Capital as a Catalyst

For Kawas, patience alone is not enough. She stresses the need for “smart capital”—investment paired with expertise, networks, and guidance. Propel Bio Partners was founded on this principle. The firm does more than provide financing; it offers strategic support to help companies anticipate challenges, refine strategies, and connect with the right partners.

Kawas draws on her own experience leading Athira Pharma. She recalls that access to knowledgeable investors and advisors often made the difference between progress and stagnation. Smart capital, she argues, is catalytic: it multiplies the impact of financial investment by ensuring companies can execute effectively.

Broadening Access to Innovation

Another dimension of Kawas’s philosophy is her focus on expanding opportunities for diverse founders. She notes in this interview with Billion Success that many brilliant scientists lack the networks or financial backing to advance their work. Without intervention, valuable discoveries can languish in laboratories rather than reaching patients.

Through Propel Bio Partners, she works to close this gap by backing founders who might otherwise be overlooked. Her belief is that broadening access to capital is not just an equity issue but a way to accelerate innovation across the sector. When more perspectives and ideas are supported, the chances of breakthrough therapies increase.

From Science to Business

Kawas’s perspective is shaped by her journey as a scientist turned entrepreneur. At Athira Pharma, she helped advance therapies targeting neurodegenerative diseases, guiding the company from early development through an IPO. That experience underscored for her the unique challenges of turning science into business: securing funding, meeting regulatory standards, and managing growth while preserving scientific integrity.

She emphasizes that life science founders often need guidance on this transition. Patient, smart capital helps bridge the gap between laboratory discovery and market delivery. Investors who understand both science and business can create conditions where innovation is not only possible but sustainable.

Aligning Capital With Purpose

Kawas often points out that life science investment carries a dual responsibility. It must deliver returns to investors, but it must also serve patients. The stakes are measured not only in dollars but in lives improved or saved. For her, this dual purpose reinforces the need for disciplined, mission-driven capital.

She argues that when investors align with this purpose, they create healthier companies and healthier industries. The most successful biotech ventures are not those that chase quick wins, but those that build enduring value by delivering therapies that matter.

A Vision for the Future

Looking ahead, Kawas envisions a biotech ecosystem where capital is both abundant and discerning. She hopes to see more investors adopt the principles of patience and strategy, recognizing that the rewards of life science are both financial and societal.

Through Propel Bio Partners, she continues to back companies that embody this vision—ventures with strong science, committed teams, and the potential to transform patient care. For Kawas, the lesson is simple: life science is too important for short-term thinking. It requires capital that is not only willing to wait but willing to think.

Leen Kawas is currently on the board of directors for Inherent Biosciences:

https://www.inherentbio.com/team/leen-kawas

Science advances through laboratories, data, and discovery, but it also advances through perspective. For Leen Kawas, co-founder and managing general partner of Propel Bio Partners, perspective has been shaped by a journey that spans continents. From her early life in Amman, Jordan, to her leadership roles in the United States, she has built a career that reflects both global awareness and deep commitment to local impact. Her view of science is not bounded by borders but defined by the belief that innovation must serve people everywhere.

Leen Kawas began her professional life as a pharmacist in Jordan, a role that grounded her in the practical realities of medicine. That early work revealed both the promise of pharmaceuticals and the limits imposed by access, infrastructure, and investment. She carried those insights with her when she moved to the United States, where she pursued advanced education and immersed herself in biotechnology. This transition gave her a dual perspective: the urgency of medical need in emerging economies and the resources available in global biotech hubs.

Her career took shape most visibly at Athira Pharma, the company she co-founded and later led as chief executive officer. Under her leadership, Athira advanced late-stage clinical programs and achieved one of the largest biotech IPOs of its time, raising over $400 million in 2020. For Kawas, the milestone was not only financial. It was evidence that diverse leadership could deliver results at the highest levels of science and business. As one of only 22 women founders in the United States to take a company public, she stood as an example of how global experience and persistence can reshape an industry often resistant to change.

The founding of Propel Bio Partners marked another step in her journey. Based in Los Angeles, the venture fund supports life science innovation by investing in companies with the potential to transform patient care. Kawas emphasizes that Propel is not simply a source of capital but a partner in strategy, growth, and scientific advancement. Her approach reflects lessons drawn from both her own entrepreneurial path and her international background: science flourishes when support is holistic, forward-looking, and rooted in collaboration.

What distinguishes Kawas’ perspective is her global lens. She argues that the challenges facing healthcare are universal. Diseases do not respect borders, and solutions must be designed with both scale and equity in mind. Having witnessed disparities in access firsthand, she advocates for approaches that consider how innovation will reach patients beyond wealthy markets. For her, a breakthrough is not truly a breakthrough until it changes lives in diverse communities.

She also stresses the importance of diversity within the scientific enterprise itself. Kawas noted in this interview with Billion Success that innovation improves when teams bring different cultural, educational, and professional perspectives to the table. At Propel, she encourages investment in founders and companies that reflect this diversity, recognizing that a global industry requires global voices. In her view, the future of science depends as much on who is doing the research as on what research is being done.

Her story underscores another lesson: the value of adaptability. Moving from Amman to the United States required navigating new systems, expectations, and networks. Leading a public company required mastering the intersection of science and capital markets. Building a venture fund required shifting again into mentorship and investment. At each stage, Kawas translated lessons across contexts, demonstrating that science is not a static career but a dynamic, evolving practice.

Kawas’ global view on science carries practical implications for the future of biotechnology. She advocates for policies and investments that close the gap between discovery and delivery, ensuring that promising therapies reach patients efficiently. She calls for greater collaboration across borders, pointing out that pandemics, climate change, and chronic diseases all demand collective action. And she highlights the need for patient-centered thinking, reminding investors and scientists alike that innovation must ultimately be measured in improved outcomes, not only in market capitalization.

The arc of her career illustrates how personal journey and professional mission can align. From Amman to Los Angeles, Kawas has carried with her a belief in the universality of science, the necessity of equity, and the power of persistence. Her work demonstrates that biotechnology is not confined to labs or boardrooms. It is shaped by the choices of leaders who bring global experiences into every decision.

For Leen Kawas, science is not an abstract pursuit. It is a shared human endeavor, requiring vision, investment, and a commitment to accessibility. Her global view reminds us that the breakthroughs of tomorrow depend on perspectives that span cultures and geographies, and on leaders who never forget that the purpose of science is to serve people everywhere.

Learn more about what Leen Kawas is currently up to below:

Leen Kawas, Ph.D., PharmSci.

For any biotech company, advancing a drug candidate into late-stage clinical trials marks both progress and pressure. The stakes are higher, the costs increase, and the timelines tighten. For Leen Kawas, scientist, entrepreneur, and co-founder of Propel Bio Partners, late-stage clinical development represents the culmination of years of research and the bridge to potential patient impact. Drawing on her experience as the former chief executive of Athira Pharma, where she led late-stage programs and an initial public offering, Kawas emphasizes that success in this stage requires more than strong science. It demands discipline, strategy, and resilience.

The Transition to Scale

Early-stage research often takes place in laboratories, with small teams exploring mechanisms of action and proof-of-concept studies. Late-stage programs are different. They move beyond initial promise into rigorous, large-scale trials that must satisfy regulators and withstand scrutiny from investors. Leen Kawas explains that this transition is one of the most challenging phases for biotech companies.

The demands of late-stage development test every part of an organization. Manufacturing must scale, clinical protocols must expand across multiple sites, and trial design must align with regulatory requirements. Kawas notes that companies succeed when they plan for this scale early, rather than waiting for late-stage pressures to force rushed decisions.

Balancing Science and Business

Kawas has long argued that late-stage programs sit at the intersection of science and business. On one side, the integrity of the research must remain uncompromised. On the other, companies must manage capital efficiently to ensure trials can be completed. She emphasizes that leaders cannot afford to focus on one dimension at the expense of the other.

At Athira, she oversaw both the scientific direction and the financial strategy. This dual focus allowed the company to progress clinical programs while raising more than $400 million through its IPO. For Kawas, advancing late-stage trials required integrating scientific insight with financial stewardship, ensuring that investors saw both credible science and clear pathways to market.

Regulatory Navigation

No late-stage program can succeed without navigating regulatory complexity. Kawas highlights the importance of early and ongoing communication with regulators to align expectations. Engaging agencies before pivotal trials begin helps avoid costly redesigns later.

She stresses that regulatory frameworks are not obstacles but structures that, when understood, guide companies toward approval. By treating regulators as partners rather than adversaries, companies can reduce uncertainty and accelerate timelines. Leen Kawas believes that proactive engagement builds credibility and demonstrates seriousness of purpose.

Building the Right Team

Late-stage clinical development is too complex for leadership to carry alone. Kawas underscores the necessity of assembling teams with deep expertise in trial design, biostatistics, operations, and regulatory affairs. These professionals bring the technical precision required to manage multi-site, multi-year studies.

She also emphasizes culture. High-pressure environments can strain teams, yet resilience and collaboration are vital to success. Kawas’s leadership style has focused on empowering experts, fostering trust, and ensuring that scientific integrity remains central even under commercial pressures. The right team, she argues, transforms daunting challenges into coordinated execution.

Patient-Centered Perspective

Amid the complexity of late-stage programs, Kawas insists on maintaining a clear focus: patients. Every protocol, every endpoint, every operational decision ultimately leads back to how a therapy will affect human lives. She argues that companies lose direction when they reduce trials to metrics without considering the people behind them.

Patient engagement also strengthens trial design. By listening to patients and incorporating their experiences into endpoints and study structures, companies increase the relevance of results. Kawas sees this as both a moral responsibility and a strategic advantage, as regulators and payers increasingly demand evidence of real-world benefit.

Resilience Through Uncertainty

Late-stage trials carry high failure rates, and setbacks are common. Kawas emphasizes resilience as a defining trait for both leaders and organizations. When data disappoints or timelines shift, the ability to adapt without losing sight of the larger mission determines long-term survival.

She encourages leaders to frame setbacks as learning opportunities. Each trial, whether successful or not, provides insights that inform future approaches. This mindset prevents discouragement from derailing momentum and ensures that the organization continues moving forward. Her interview with Principal Post explores this in further detail.

Looking Ahead

As biotechnology continues to evolve, the demands of late-stage clinical programs will only grow. Rising costs, heightened competition, and increasing scrutiny make this stage more challenging than ever. Yet for Kawas, these pressures also highlight the importance of disciplined, patient-centered leadership.

Her experience shows that advancing late-stage programs requires more than science alone. It requires planning for scale, integrating business and research, building resilient teams, and keeping patients at the center. When executed with care, these programs have the power to translate scientific discovery into therapies that change lives.

Leen Kawas’s career demonstrates that the path from laboratory bench to late-stage clinical success is arduous but achievable. By blending scientific insight with entrepreneurial skill, she has shown that biotech leaders can carry innovations across the threshold where they become not only trials but potential treatments.

To learn more about the work Leen Kawas is doing, check out her profile on Crunchbase.com.